Ellen Koenig

2.2k total citations · 1 hit paper
23 papers, 822 citations indexed

About

Ellen Koenig is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Ellen Koenig has authored 23 papers receiving a total of 822 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Infectious Diseases, 14 papers in Virology and 6 papers in Epidemiology. Recurrent topics in Ellen Koenig's work include HIV/AIDS drug development and treatment (18 papers), HIV Research and Treatment (14 papers) and HIV/AIDS Research and Interventions (10 papers). Ellen Koenig is often cited by papers focused on HIV/AIDS drug development and treatment (18 papers), HIV Research and Treatment (14 papers) and HIV/AIDS Research and Interventions (10 papers). Ellen Koenig collaborates with scholars based in United States, Thailand and France. Ellen Koenig's co-authors include Andrew Cheng, Edwin DeJesus, Erin Quirk, Joseph M. Custodio, Kirsten White, Andrea Antinori, Paul E. Sax, Jihad Slim, Devi SenGupta and Will Garner and has published in prestigious journals such as The Lancet, Gastroenterology and Journal of Clinical Microbiology.

In The Last Decade

Ellen Koenig

23 papers receiving 804 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

2017 278 citations Paul E. Sax, Anton Pozniak et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ellen Koenig United States	12	760	533	275	145	56	23	822
Dan Duiculescu Romania	11	805 1.1×	628 1.2×	219 0.8×	225 1.6×	32 0.6×	22	949
José Valdez Madruga Brazil	7	775 1.0×	600 1.1×	154 0.6×	181 1.2×	21 0.4×	11	829
Kati Vandermeulen Belgium	12	651 0.9×	480 0.9×	177 0.6×	133 0.9×	54 1.0×	19	713
Miguel Goicoechea United States	10	467 0.6×	282 0.5×	183 0.7×	129 0.9×	39 0.7×	24	572
Roland Landman France	16	815 1.1×	541 1.0×	152 0.6×	242 1.7×	37 0.7×	63	917
Vadim Pokrovskiy Russia	6	754 1.0×	563 1.1×	296 1.1×	146 1.0×	19 0.3×	13	828
Roberto Ortiz United States	8	967 1.3×	624 1.2×	250 0.9×	275 1.9×	20 0.4×	17	1.0k
Gordon Crofoot United States	14	811 1.1×	510 1.0×	289 1.1×	273 1.9×	59 1.1×	27	981
Lynette Purdue United States	15	572 0.8×	444 0.8×	140 0.5×	168 1.2×	47 0.8×	17	746
Jan Fourie United States	10	882 1.2×	678 1.3×	190 0.7×	149 1.0×	32 0.6×	13	939

Countries citing papers authored by Ellen Koenig

Since Specialization

Citations

This map shows the geographic impact of Ellen Koenig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellen Koenig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellen Koenig more than expected).

Fields of papers citing papers by Ellen Koenig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellen Koenig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellen Koenig. The network helps show where Ellen Koenig may publish in the future.

Co-authorship network of co-authors of Ellen Koenig

This figure shows the co-authorship network connecting the top 25 collaborators of Ellen Koenig. A scholar is included among the top collaborators of Ellen Koenig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ellen Koenig. Ellen Koenig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Avihingsanon, Anchalee, Hongzhou Lu, Chee Loon Leong, et al.. (2023). 330 WEEK 48 RESULTS OF A PHASE 3 RANDOMIZED CONTROLLED TRIAL OF BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (B/F/TAF) VS DOLUTEGRAVIR + EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE (DTG+F/TDF) IN ART-NAIVE, HIV/HBV-COINFECTED ADULTS (ALLIANCE). Gastroenterology. 164(6). S–1241. 1 indexed citations

2.

Avihingsanon, Anchalee, Hongzhou Lu, Chee Loon Leong, et al.. (2023). Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial. The Lancet HIV. 10(10). e640–e652. 32 indexed citations

3.

Gupta, Samir K., Mezgebe Berhe, Gordon Crofoot, et al.. (2022). Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial. The Lancet HIV. 10(1). e15–e23. 65 indexed citations

4.

Orkin, Chloe, Faïza Ajana, Cissy Kityo, et al.. (2021). Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials. JAIDS Journal of Acquired Immune Deficiency Syndromes. 88(4). 393–398. 5 indexed citations

5.

Orkin, Chloe, Faïza Ajana, Cissy Kityo, et al.. (2021). Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials.. PubMed. 88(4). 393–398. 2 indexed citations

6.

Kityo, Cissy, Debbie Hagins, Ellen Koenig, et al.. (2019). Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial. JAIDS Journal of Acquired Immune Deficiency Syndromes. 82(3). 321–328. 44 indexed citations

7.

Daar, Eric S., Edwin DeJesus, Peter Ruane, et al.. (2018). Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. The Lancet HIV. 5(7). e347–e356. 117 indexed citations

8.

Sax, Paul E., Anton Pozniak, Marisa Montes, et al.. (2017). Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. The Lancet. 390(10107). 2073–2082. 278 indexed citations breakdown →

9.

Daar, Eric S., Edwin DeJesus, Peter Ruane, et al.. (2017). Phase 3 Randomized, Controlled Trial of Switching to Fixed-dose Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Boosted Protease Inhibitor-based Regimens in Virologically Suppressed Adults: Week 48 Results. Open Forum Infectious Diseases. 4(suppl_1). S735–S735. 4 indexed citations

10.

Squires, Kathleen, Cissy Kityo, Sally Hodder, et al.. (2016). Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study. The Lancet HIV. 3(9). e410–e420. 62 indexed citations

11.

Koenig, Ellen. (2016). Changes in renal laboratory parameters and bone mineral density in treatment-naïve HIV-1-infected adolescents initiating therapy with INSTI-based single-tablet regimens containing tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF). Journal of the International AIDS Society. 19(2). 1 indexed citations

12.

DeJesus, Edwin, Michael T. Yin, Frank Post, et al.. (2015). P030: Renal and bone safety of tenofovir alafenamide versus tenofovir disoproxil fumarate. Journal of the International AIDS Society. 18(3 (Suppl 2)). 9 indexed citations

13.

Gallant, Joel E., Ellen Koenig, Jaime Andrade‐Villanueva, et al.. (2015). Brief Report. JAIDS Journal of Acquired Immune Deficiency Syndromes. 69(3). 338–340. 17 indexed citations

14.

Koenig, Ellen, et al.. (2015). P002: Clinical manifestations of Chikungunya virus infection in HIV-infected individuals: experiences during the Dominican Republic's 2014 outbreak. Journal of the International AIDS Society. 18(3 (Suppl 2)). 9 indexed citations

15.

Gallant, Joel E., Ellen Koenig, Jaime Andrade‐Villanueva, et al.. (2013). Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results. The Journal of Infectious Diseases. 208(1). 32–39. 84 indexed citations

16.

Novák, Richard, Barbara Metch, Susan Buchbinder, et al.. (2013). Risk behavior among women enrolled in a randomized controlled efficacy trial of an adenoviral vector vaccine to prevent HIV acquisition. AIDS. 27(11). 1763–1770. 11 indexed citations

17.

López, Pablo A., et al.. (2010). Distribution of HIV-1 Infection in Different T Lymphocyte Subsets: Antiretroviral Therapy-Naïve vs. Experienced Patients. AIDS Research and Human Retroviruses. 27(4). 399–410. 5 indexed citations

18.

Gupta, Swati B., Gary Murphy, Ellen Koenig, et al.. (2007). Comparison of Methods to Detect Recent HIV Type 1 Infection in Cross-Sectionally Collected Specimens from a Cohort of Female Sex Workers in the Dominican Republic. AIDS Research and Human Retroviruses. 23(12). 1475–1480. 14 indexed citations

19.

Koenig, Ellen, et al.. (1996). [IgM Leptospira antibodies in acute infectious hepatitis cases in children].. PubMed. 27(2). 39–41. 2 indexed citations

20.

Espinal, Marcos, et al.. (1995). Screening for active tuberculosis in HIV testing centre. The Lancet. 345(8954). 890–893. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact